NetworkNewsBreaks – Lexaria Bioscience Corp. (CS
Post# of 721
(Total Views: 165)
Posted On: 04/09/2019 3:55:16 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Renews Senior Management Contracts, Cancels Options
Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this morning announced its successful negotiation of renewal management contracts with chief executive officer Chris Bunka and president John Docherty. According to the update, the new 3-year term contracts, for which specific details can be found within regulatory filings, provide management continuity during this period of corporate growth while allowing the company to seamlessly pursue its business goals and create shareholder value. In addition, Lexaria announced that, effective April 5, 2019, it has reached agreements with certain optionees to cancel 1,140,000 stock options with exercise prices ranging from $0.10 to $2.06.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this morning announced its successful negotiation of renewal management contracts with chief executive officer Chris Bunka and president John Docherty. According to the update, the new 3-year term contracts, for which specific details can be found within regulatory filings, provide management continuity during this period of corporate growth while allowing the company to seamlessly pursue its business goals and create shareholder value. In addition, Lexaria announced that, effective April 5, 2019, it has reached agreements with certain optionees to cancel 1,140,000 stock options with exercise prices ranging from $0.10 to $2.06.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)